Navigation Links
Boiron Laboratories Disputes British Journal's Editorial on Homeopathy
Date:11/27/2007

NEWTOWN SQUARE, Pa., Nov. 27 /PRNewswire/ -- In its continued educational and research efforts for the advancement of homeopathy, Boiron Laboratories disputes an editorial comment published in The Lancet's Nov. 17, 2007 issue on the basis that its author has misinterpreted results of clinical trials on homeopathic medicines. (1-5)

The British medical journal features an editorial by Ben Goldacre on the "Benefits and Risks of Homeopathy." In his commentary, Goldacre suggests that the results from five large meta-analyses indicate that homeopathy produces no statistically significant benefit over placebo.

However, a thorough review of the studies' research evidence indicates positive principle conclusions in favor of homeopathy over placebo as quoted as follows:

1. The Kleijnen, et al(1) study states that "the evidence of clinical

trials is positive but not sufficient to draw any definite

conclusions."

2. The Boissel, et al(2) study reports that "[f]or 17 retained

comparisons, for each method used, the result is a p-value well below

.0001. This means that in at least one test, the null hypothesis (lack

of effect of homeopathy) must be rejected. ... The number of

significant results is not likely due to chance alone."

3. The Linde, et al(3) study concludes that "[t]he results of the

available randomized trials suggest that individualized homeopathy has

an effect over placebo."

4. The Cucherat, et al(4) study concludes that "[t]here is evidence that

homeopathic treatments are more effective than placebo."

5. The Shang, et al(5) study indicates that "21 (19 percent) homeopathic

trials and nine (8 percent) conventional medicine tests were of higher

quality. Most odds ratios indicated a beneficial effect of the

intervention. Heterogeneity of trial results was less pronounced for

homeopathy ... than conventional medicine .... This difference is

unlikely to be due to chance (p=0.011 by F test)."

Additionally, there is a sixth relevant meta-analysis(6) also published in The Lancet that supports positive results for homeopathy, but was not mentioned in Goldacre's commentary. The study authors concluded that "the results of our meta-analysis are not compatible with the hypothesis that the clinical effects of homeopathy are completely due to a placebo effect."

About Boiron: Boiron, world leader in homeopathy, is a $500 million public company with 3,800 employees in more than 60 countries. It produces more than 1,500 homeopathic medicines. For over 70 years, Boiron has been committed to funding scientific research and educating the public and healthcare professionals on homeopathic medicines. Boiron maintains the highest manufacturing standards, complying with U.S. Food and Drug Administration regulations, the Homeopathic Pharmacopoeia of the United States and drug Good Manufacturing Practices.

References

1. Kleijnen J, Knipschild P, ter Riet G. Clinical trials of homeopathy.

BMJ 1991; 302: 316-23.

2. Boissel JP, Cucherat M, Haugh M, Gauthier E. Critical literature review

on the effectiveness of homoeopathy: overview of data from homeopathic

medicine trials. Brussels, Belgium: Homoeopathic Medicine Research

Group. Report to the European Commission. 1996; 195-210.

3. Linde K, Melchart D. Randomized controlled trials of individualized

homeopathy: a state-of-the-art review. J Alter Complement Med 1998;

4: 371-88.

4. Cucherat M, Haugh MC, Gooch M, Boissel JP. Evidence of clinical

efficacy of homeopathy: a meta-analysis of clinical trials. Eur JClin

Pharmacol 2000; 56: 27-33.

5. Shang A, Huwiler-Muntener K, Nartey L, et al. Are the clinical effects

of homeopathy placebo effects? Comparative study of placebo-controlled

trials of homeopathy and allopathy. The Lancet 2005; 366: 726-32.

6. Linde K, Clausius N, Ramirez H, et al. Are the clinical effects of

homeopathy placebo effects? A meta-analysis of placebo-controlled

trials. The Lancet 1997; 350: 834-43. Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Ronald Boyer, M.D. http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=58078 Christophe Merville http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=56842


'/>"/>
SOURCE Boiron Laboratories
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
5. Sandia National Laboratories Selects Allscripts Electronic Health Record and Practice Management for Employee Health Center
6. Andrew Lessmans TWC Construction and ProCaps Laboratories Contract With DT Solar to Install a 700 kW Solar Electric System
7. Mesa Laboratories Names New Vice President of Sales and Marketing
8. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
9. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings
10. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
11. JDRF partners with Housey Pharmaceutical Research Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 2016 , ... Two director-level employees of Horizon Blue Cross Blue Shield of ... 2016 honorees. The award recognizes businesswomen who excel in their fields and who ... the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health and Theresa ...
(Date:5/27/2016)... ... 2016 , ... With over 60 percent of acute stroke survivors being left ... to aid in the rehabilitation process has steadily increased. Ekso Bionics had been working ... due to stroke. , Ekso Bionics has now received clearance from the U.S. Food ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... help educate the many who are unaware of the plight of aphasia. In ... run within the “Stroke Awareness” campaign. , The link between stroke and aphasia ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees in ... come courtesy of leaders in the nursing and health care industry. It also provides ... associations—namely Abilene Christian University. , As the nursing industry is coming out of ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting at a ... to wait until March 2017 for an interest rate increase, according to Rajeev Dhawan ... Business. , “The Federal Open Market Committee (FOMC) dot charts are of interest to ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... , May 26, 2016 ... Associated With Both Cost Savings and Overall ... plc (LSE: BTG), an international specialist healthcare company, ... at the 21st Annual Meeting of ISPOR (International ... treatment of hepatocellular carcinoma (HCC) using yttrium-90 glass ...
(Date:5/25/2016)... 25, 2016 According to a ... (3D, 2D, 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), ... (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast to 2021", ... Animation Market for the forecast period of 2016 to ... Million by 2021 from USD 117.3 Million in 2016, ...
(Date:5/25/2016)... , May 25, 2016  According to Kalorama Information, ... billion in 2015.  Though these are challenging times ... opportunity for success for companies that remain optimistic ... of new growth prospects medical device companies spend ... and development (R&D) than do companies in other ...
Breaking Medicine Technology: